Aurobindo Pharma rises on eyeing production commencement in China facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 1517.20, up by 14.90 points or 0.99% from its previous closing of Rs. 1502.30 on the BSE.
The scrip opened at Rs. 1502.30 and has touched a high and low of Rs. 1536.35 and Rs. 1490.90 respectively. So far 13362 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,536.35 on 19-Aug-2024 and a 52 week low of Rs. 815.15 on 05-Sep-2023.
Last one week high and low of the scrip stood at Rs. 1536.35 and Rs. 1422.00 respectively. The current market cap of the company is Rs. 88429.85 crore.
The promoters holding in the company stood at 51.80%, while Institutions and Non-Institutions held 41.50% and 6.70% respectively.
Aurobindo Pharma is eyeing to commence production in its China facility in the next quarter with full-scale output anticipated only in the next fiscal year. The Hyderabad-based drug major plans to start a small volume roll out in the November-December period and expects to ramp it up in the January-March quarter of the next year.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
